Yahoo Web Search

Search results

1. • Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer...

     The Grass Valley Union· 3 days ago

     Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases ...

2. • Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix

     Morningstar· 9 hours ago

     INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALSThe study investigated 123 metastatic ovarian ...

3. • Small Business - The Andalusia Star-News | The Andalusia Star-News

     The Andalusia Star-News· 2 hours ago

     Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic ...

4. • Home BP Self-Monitoring Plus Self-Titration for Patients With Hypertension

     Journal of the American Medical Association· 6 days ago

     This prespecified secondary analysis of the ADAMPA randomized clinical trial evaluates blood pressure (BP) control at 24 months with self-management based on home BP monitoring plus self-titration ...

5. • Small Business - Shelby County Reporter | Shelby County Reporter

     The Shelby County Reporter· 7 days ago

     Rakuten Medical Announces Poster Presentation and Booth Exhibition at ASCO 2024 Annual Meeting PR Newswire SAN DIEGO, May 9, 2024 - Poster will highlight interim evaluation update of photoimmunotherapy based on Alluminox™ platform using ASP-1929

6. • 

     GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update

     NewMediaWire via Yahoo Finance· 2 days ago

     Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven...

7. • The National Kidney Foundation's 2024 Spring Clinical Meetings Late-Breaking Presentation on New...

     WFRV 5 Green Bay· 2 days ago

     During a late-breaking abstract presentation at the annual 2024 NKF Spring Clinical Meetings (SCM) tomorrow Dr. Dana Rizk, from the University of Alabama at Birmingham (UAB) Medical Center, ...

8. • Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis -...

     Benzinga· 1 day ago

     Celldex Therapeutics, Inc. CLDX today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is ...

9. • Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by...

     Benzinga· 4 days ago

     The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, including robust intracranial responses Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today

10. • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter...

      Morningstar· 3 days ago

      ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD